Literature DB >> 231404

Prostaglandins and their regulation in rheumatoid inflammation.

D R Robinson, J M Dayer, S M Krane.   

Abstract

Prostaglandins, especially PGE2 and PGI2, appear to participate in the development of inflammatory reactions. While these PGs may act to promote inflammation, they may also inhibit immune reactions; this effect is largely related to stimulation of adenylate cyclase. Human rheumatoid synovial tissue explants and derived adherent synovial cells (ASC) in vitro produce large amounts of PG, primarily PGE2, which may participate in the pathogenesis of rheumatoid inflammation and promote the osteoclastic resorption of juxtaarticular bone. Rheumatoid synovial organ cultures are unusual in that they derive a significant proportion of archidonic acid substrate for the PGE2 synthesis from triglycerides, while ASC utilize primarily phospholipids. Aspirin-like, nonsteroidal anti-inflammatory drugs inhibit PGE2 synthesis by rheumatoid synovial organ cultures at concentrations similar to those achieved in plasma during therapy. Glucocorticoids are also potent inhibitors of PGE2 synthesis, and evidence from experiments with tissue labeled with 1-[14C]arachidonic acid indicates that glucocorticoids do not act to inhibit arachidonic acid release, as has been postulated for other tissues. Human peripheral blood mononuclear cells produce a factor (MCF) that regularly stimulates the production of PGE2 and collagenase from resting ASC often by over 100-fold. The MCF appears to be produced by monocytes, and its production by monocytes is enhanced by lectin-stimulated T-cells. The ability of ASC to respond to exogenous PGE2 stimulation of cAMP synthesis is inhibited or stimulated by factors that increase or decrease PGE2 levels, respectively, in the cultures. The MCF augments the responsiveness of cAMP response to PGE2 in indomethacin-treated cultures. These in vitro experiments suggest that the pathogenesis of rheumatoid inflammation involves interactions between monocyte-macrophages, lymphocytes, and synovial cells regulating the production of PGE2, cAMP, and other factors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 231404     DOI: 10.1111/j.1749-6632.1979.tb47122.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  Targeting rheumatoid inflammation and joint destruction in the mouse.

Authors:  Masaki Inada; Stephen M Krane
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 2.  Prostaglandins, thromboxanes and leukotrienes in clinical medicine.

Authors:  R D Zipser; G Laffi
Journal:  West J Med       Date:  1985-10

3.  The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype.

Authors:  Maaike M B W Dooper; Lianne Wassink; Laura M'Rabet; Yvo M F Graus
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

4.  Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis.

Authors:  O Laitinen; E Seppalä; M Nissilä; H Vapaatalo
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

Review 5.  The arachidonic acid cascade. The prostaglandins, thromboxanes and leukotrienes.

Authors:  E Granström
Journal:  Inflammation       Date:  1984-06       Impact factor: 4.092

Review 6.  Cellular basis and oncogene expression of rheumatoid joint destruction.

Authors:  S Gay; R E Gay
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

7.  Pathway analysis of seven common diseases assessed by genome-wide association.

Authors:  Ali Torkamani; Eric J Topol; Nicholas J Schork
Journal:  Genomics       Date:  2008-09-16       Impact factor: 5.736

8.  Immune complex induced arthritis in rats: role of lipid mediators on cell infiltration.

Authors:  F A Rocha; L E Andrade; S Jancar
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.